Biotechnology in reproductive medicine.
In this review I am summarizing the past and current progress in the field of pharmaceutical, diagnostic, therapeutic, and reproductive cloning in mammals. Several human gene products can be pharmaceutically explored in transgenic farm animals and employed for medical applications. Preimplantation genetic diagnosis (PGD) is utilizing modern molecular cloning techniques to detect genetic and chromosomal aberrations in early embryos originating from patients with inborn errors at risk for hereditary diseases or age-related risk for abnormal karyotype. Stem cell engineering from early human embryos is creating new and promising but also controversial applications for therapeutic and regenerative medicine. Potential risk factors for reproductive cloning are presented and discussed in the context of possible developmental malformations, frequently observed after embryo culture and cloning in farm animals. Future extension of biotechnology to human reproductive cloning is currently under worldwide dispute.
Illmensee
Karl
K
Department of Gynaecology and Obstetrics, University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria. johanna.ulmer@uibk.ac.at
D000818:Animals; D030801:Animals, Genetically Modified / Q000002:abnormalities; D001709:Biotechnology / Q000379:methods / Q000639:trends*; D019976:Cloning, Organism / Q000009:adverse effects / Q000639:trends* / Q000662:veterinary; D004345:Drug Industry / Q000639:trends; D030342:Genetic Diseases, Inborn / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D019836:Preimplantation Diagnosis; D018456:Reproductive Medicine / Q000639:trends*; D012307:Risk Factors; D033581:Stem Cell Transplantation